Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome. Issue 7 (18th October 2021)

• Record Type: Journal Article
• Authors: Egan-Sherry, Dana; Bhuta, Roma; Cole, Peter D.; Gennarini, Lisa M.; Kahn, Justine M.; Sulis, Maria Luisa; DeNardo, Bradley D.; Welch, Jennifer J.G.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 43:Issue 7(2021)
• Page Start: e997
• Page End: e999
• Publication Date: 2021-10-18
• Subjects: vincristine -- neurotoxicity -- acute lymphoblastic leukemia; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002114
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Vincristine, a key agent in the treatment of many pediatric malignancies, causes sensory, motor and autonomic neuropathy. We report the clinical courses of 5 patients who required cessation of vincristine after developing severe neurotoxicity during treatment for acute lymphoblastic leukemia. All 5 patients lost the ability to ambulate and 3 had additional severe neurotoxic side effects including vision loss and vocal cord dysfunction. Although prior literature reports poor outcomes for children in whom vincristine was discontinued during acute lymphoblastic leukemia therapy, all 5 patients described here achieved and have maintained complete continuous remission.